Belzutifan for advanced kidney cancer: long-term follow-up
Studies looking at the genes of people with kidney cancer have shown [...]
ESMO 2023: Belzutifan for the treatment of advanced kidney cancer
Treatments for people with metastatic kidney cancer have changed over [...]
SMC approves belzutifan for VHL kidney cancer in Scotland
We are delighted to announce that the Scottish Medicines Consortium [...]
Belzutifan significantly delays progression of advanced kidney cancer after other treatments have failed
Kidney cancers often have mutations in a gene called the von Hippel-Lindau [...]
Belzutifan plus cabozantinib combination shows promising results in kidney cancer
Kidney cancers often have mutations in a gene called the [...]
Three years follow-up data from the belzutifan study for pre-treated metastatic kidney cancer
Studies looking at the genes of people with kidney cancer [...]
ESMO 2021: Belzutifan (MK-6482) plus cabozantinib for advanced clear cell RCC
Kidney cancers frequently have mutations in the von Hippel-Lindau (VHL) [...]
FDA approves belzutifan for VHL kidney cancer
The FDA has approved a new drug called belzutifan for [...]
EIKCS 2021: Future treatments for metastatic kidney cancer
Despite the advances in first-line treatments for metastatic renal cell [...]
FDA grants priority review for HIF-2α inhibitor belzutifan (MK-6482)
The US Food and Drug Administration (FDA) has granted priority [...]
